Chris Conn
Global Head, Diagnostics Amgen
Christopher Conn is the Global Head of Diagnostics in the Center for Technology and Innovation within Amgen’s Precision Medicine organization. He leads the clinical diagnostic development team, overseeing end-to-end diagnostic programs from early through late-stage clinical development. He brings extensive cross-functional experience across the diagnostic and pharmaceutical industries, spanning product concept development through commercialization. Throughout his career, Christopher has led companion diagnostic programs across oncology and non-oncology therapeutic areas. He earned a Ph.D. in cell and molecular biology from the University of Cincinnati College of Medicine and completed postdoctoral training at St. Jude Children’s Research Hospital and the University of Colorado.
Seminars
- Determining how much molecular change justifies a switch when the scan still reads stable
- Weighing the risk of switching too early against the cost of waiting for radiographic confirmation
- Establishing what evidence oncologists and payers need before molecular progression becomes an accepted trigger
